Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) (PrE0905)
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for a particular change in AML of their leukemia cells (called a mutation) in a gene called FLT3.
AML with FLT3 mutation status (includes signal ratio) Verified confirmation that blasts are myeloid Verified NPM1 mutation status Must have an ECOG performance status of 0-3 Must have adequate organ function as measured by criteria
Exclusion Criteria:
May not have M3 AML May not have known active Central Nervous System (CNS) leukemia Not a woman of childbearing potential (WOCBP) or who agrees to follow the contraceptive guidance May not have a history of Long QT Syndrome May not have evidence of uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or congestive heart failure